0001854270-24-000013.txt : 20240202 0001854270-24-000013.hdr.sgml : 20240202 20240202172438 ACCESSION NUMBER: 0001854270-24-000013 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240201 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KNOBELMAN DEBORAH CENTRAL INDEX KEY: 0001931509 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40440 FILM NUMBER: 24592881 MAIL ADDRESS: STREET 1: C/O SENTI BIOSCIENCES, INC. STREET 2: 2 CORPORATE DRIVE FIRST FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Senti Biosciences, Inc. CENTRAL INDEX KEY: 0001854270 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 862437900 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 CORPORATE DRIVE, FIRST FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 382-3281 MAIL ADDRESS: STREET 1: 2 CORPORATE DRIVE, FIRST FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Senti Biosciences, Inc.\ DATE OF NAME CHANGE: 20220615 FORMER COMPANY: FORMER CONFORMED NAME: Dynamics Special Purpose Corp. DATE OF NAME CHANGE: 20210331 4 1 wk-form4_1706912660.xml FORM 4 X0508 4 2024-02-01 0 0001854270 Senti Biosciences, Inc. SNTI 0001931509 KNOBELMAN DEBORAH C/O SENTI BIOSCIENCES, INC. 2 CORPORATE DRIVE FIRST FLOOR SOUTH SAN FRANCISCO CA 94080 0 1 0 1 Chief Financial Officer Head of Corporate Development 0 Common Stock 2024-02-01 4 A 0 101000 0 A 131000 D Stock Option (Right to Buy) 0.46 2024-02-01 4 A 0 152000 0 A 2034-01-31 Common Stock 152000 152000 D The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award vest in three substantially equal annual installments over three years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date. The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2024, subject to the reporting person's continued service through the applicable vesting date. /s/ Mike Rhee, attorney-in-fact 2024-02-02